Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -47.18% is in line with its 5-year average of -45.00%, around the middle of its 5-year range (-87.20%–-23.43%).
As of the fiscal period ended Tuesday, June 30, 2026. 17.17% below its 12-month average of -40.26%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -47.18%.
RETURN ON INVESTED CAPITAL (ROIC)
-47.18%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-40.26%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-50.61%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-45.00%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-53.54%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-17.17%
CURRENT VS 3Y AVG
+6.79%
CURRENT VS 5Y AVG
-4.83%
CURRENT VS 10Y AVG
+11.89%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
-32.35%
vs the sector median at left
Protara Therapeutics, Inc.
Market Cap
$143.60M
Return on Invested Capital (ROIC)
-47.18%
TTM Avg
-40.26%
3Y Avg
-50.61%
5Y Avg
-45.00%
Market Cap
$143.84M
Return on Invested Capital (ROIC)
-223.90%
TTM Avg
-825.42%
3Y Avg
-606.12%
5Y Avg
-416.73%
Market Cap
$143.10M
Return on Invested Capital (ROIC)
-61.13%
TTM Avg
-65.92%
3Y Avg
-49.38%
5Y Avg
-37.06%
Market Cap
$146.27M
Return on Invested Capital (ROIC)
-10.85%
TTM Avg
-101.00%
3Y Avg
-120.85%
5Y Avg
-96.47%
Market Cap
$146.28M
Return on Invested Capital (ROIC)
-23.41%
TTM Avg
-38.99%
3Y Avg
-40.72%
5Y Avg
-30.95%
Market Cap
$146.62M
Return on Invested Capital (ROIC)
-118.67%
TTM Avg
-87.91%
3Y Avg
-55.09%
5Y Avg
-41.64%
Market Cap
$139.84M
Return on Invested Capital (ROIC)
-100.04%
TTM Avg
-99.87%
3Y Avg
-64.81%
5Y Avg
-51.77%
Market Cap
$139.47M
Return on Invested Capital (ROIC)
-50.04%
TTM Avg
-28.33%
3Y Avg
-324.90%
5Y Avg
-237.35%
Market Cap
$139.04M
Return on Invested Capital (ROIC)
-32.73%
TTM Avg
-84.24%
3Y Avg
-68.85%
5Y Avg
-57.28%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | $143.60M | -47.18% | -40.26% | -50.61% | -45.00% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $143.84M | -223.90% | -825.42% | -606.12% | -416.73% |
| Nyxoah S.A. (NYXH)vs › | $143.10M | -61.13% | -65.92% | -49.38% | -37.06% |
| Fortress Biotech, Inc. (FBIOP)vs › | $146.27M | -10.85% | -101.00% | -120.85% | -96.47% |
| Codexis, Inc. (CDXS)vs › | $146.28M | -23.41% | -38.99% | -40.72% | -30.95% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | -118.67% | -87.91% | -55.09% | -41.64% |
| Sutro Biopharma, Inc. (STRO)vs › | $139.84M | -100.04% | -99.87% | -64.81% | -51.77% |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | -50.04% | -28.33% | -324.90% | -237.35% |
| Immuneering Corporation (IMRX)vs › | $139.04M | -32.73% | -84.24% | -68.85% | -57.28% |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | -27.25% | -49.08% | -43.31% | -52.54% |
ROIC
-47.2%
ROE
-43.4%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -47.18% |
| 2026-03-31 | -38.28% |
| 2025-12-31 | -32.51% |
| 2025-09-30 | -44.37% |
| 2025-06-30 | -38.97% |
| 2025-03-31 | -31.84% |
| 2024-12-31 | -28.83% |
| 2024-09-30 | -53.70% |
| 2024-06-30 | -46.10% |
| 2024-03-31 | -73.02% |
| 2023-12-31 | -59.90% |
| 2023-09-30 | -87.20% |
| 2023-06-30 | -76.08% |
| 2023-03-31 | -65.92% |
| 2022-12-31 | -62.35% |
| 2022-09-30 | -25.96% |
| 2022-06-30 | -26.88% |
| 2022-03-31 | -28.27% |
| 2021-12-31 | -28.22% |
| 2021-09-30 | -26.08% |
| 2021-06-30 | -23.43% |
| 2021-03-31 | -20.02% |
| 2020-12-31 | -17.20% |
| 2020-09-30 | -11.74% |
| 2020-06-30 | -28.36% |
| 2020-03-31 | -17.14% |
| 2019-12-31 | -43.11% |
| 2019-09-30 | -12.94% |
| 2019-06-30 | -94.14% |
| 2019-03-31 | -84.70% |
| 2018-12-31 | -85.11% |
| 2018-09-30 | -86.78% |
| 2018-06-30 | -114.25% |
| 2018-03-31 | -102.61% |
| 2017-12-31 | -87.42% |
| 2017-09-30 | -80.19% |
| 2017-06-30 | -89.89% |
| 2017-03-31 | -85.97% |
| 2016-12-31 | -74.69% |
| 2016-09-30 | -62.96% |
| 2016-06-30 | -50.94% |
| 2016-03-31 | -39.95% |
| 2015-12-31 | -32.91% |
| 2015-09-30 | -25.97% |
| 2015-06-30 | -17.26% |
